September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Ranibizumab treatment according to the subtypes of choroidal neovascularisation due to neovascular Age-related Macular Degeneration in a real-life. 3 years interim analysis of a French national observational and multicentric retrospective study: COLOR.
Author Affiliations & Notes
  • David Sayag
    Rétina, Centre Exploration Vision, PARIS, France
  • Florence Coscas
    Centre Ophtalmologique de l'Odéon, Paris, France
  • Gerard Mimoun
    Centre Ophtalmologique d'Imagerie de l'Ecole Militaire, Paris, France
  • Catherine Favard
    Centre Ophtalmologique de l'Odéon, Paris, France
  • Catherine Francais-Maury
    Centre Ophtalmologique de l'Odéon, Paris, France
  • Valerie Krivosic
    Centre Ophtalmologique de l'Odéon, Paris, France
  • Vincent Pierre-Kahn
    Rétina, Centre Exploration Vision, PARIS, France
  • Footnotes
    Commercial Relationships   David Sayag, None; Florence Coscas, None; Gerard Mimoun, None; Catherine Favard, None; Catherine Francais-Maury, None; Valerie Krivosic, None; Vincent Pierre-Kahn, None
  • Footnotes
    Support  NOVARTIS
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3368. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Sayag, Florence Coscas, Gerard Mimoun, Catherine Favard, Catherine Francais-Maury, Valerie Krivosic, Vincent Pierre-Kahn; Ranibizumab treatment according to the subtypes of choroidal neovascularisation due to neovascular Age-related Macular Degeneration in a real-life. 3 years interim analysis of a French national observational and multicentric retrospective study: COLOR.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3368.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe three years results of intravitreal (IVT) ranibizumab treatment in patients with neovascular age-related macular degeneration (nAMD) according to the subtypes of choroidal neovascularisation (CNV).

Methods : A retrospective, multicentric, non-interventional study conducted at 3 sites in France in October 2015. Patients aged ≥65 years with CNV secondary to nAMD treated with ranibizumab and followed up over 3 years between January 2007 and March 2015 were included. CNV lesions were classified as occult CNV (type 1), classic CNV (type 2) or retinal angiomatous proliferation (type 3). Treatment responses were monitored by visual acuity (VA) testing (ETDRS score), fluorescein angiography and optical coherence tomography (OCT). Data from patient’s medical charts were collected at diagnosis and at 3, 12, 24 and 36 months (±1 month) after ranibizumab initiation. Data from an interim analysis are presented here.

Results : A total of 143 patients (81 right eyes and 62 left eyes) were included in this interim analysis (92 females, 64.3%; mean age, 78.2±7.1 years). Mean time from initial diagnosis to start of ranibizumab was 3.4±13.1 weeks. Baseline VA was 58.6±14.6 ETDRS letters. Lesions were predominantly retrofoveal (n=106, 74.1%). CNV subtype was predominantly type 1 (70.6%), followed by type 2 (20.3%) and type 3 (9.1%). Mean number of IVT injections received in the first, second and third year was 5.5, 2.7 and 2.6 for type 1; 4.8, 2.7 and 2.0 for type 2, and 5.6, 3.1 and 2.5 for type 3, respectively. Three years’ treatment with ranibizumab resulted in visual acuity stabilization (mean BCVA: -0.4 letters). Fibrosis and atrophy progression were predominant in type 2 and type 3 lesions respectively. At Month 36, 106 (74.1%) patients were still receiving IVT ranibizumab and 8 were given other therapy; few had been switched to another anti-VEGF (n=3).

Conclusions : The results of this study show that VA was maintained after 3 years of IVT. Fibrosis and atrophy progressions seemed to be more related to type 2 and type 3 lesions, respectively.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×